This study assessed and compared the immunogenicity of various immunization strategies in mice using combinations of recombinant DNA (pCCMp24) and recombinant attenuated vaccinia virus Tian Tan (rddVTT -CCMp24 ). Intramuscular immunization was performed on days 0 (prime) and 21 (boost). The immunogenicity of the vaccine schedules was determined by measuring human immunodeficiency virus (HIV)-specific binding antibody levels and cytokine (interleukin-2 and interleukin-4) concentrations in peripheral blood, analyzing lymphocyte proliferation capacity against HIV epitopes and CD4 
This study assessed and compared the immunogenicity of various immunization strategies in mice using combinations of recombinant DNA (pCCMp24) and recombinant attenuated vaccinia virus Tian Tan (rddVTT -CCMp24 ). Intramuscular immunization was performed on days 0 (prime) and 21 (boost) . The immunogenicity of the vaccine schedules was determined by measuring human immunodeficiency virus (HIV)-specific binding antibody levels and cytokine (interleukin-2 and interleukin-4) concentrations in peripheral blood, analyzing lymphocyte proliferation capacity against HIV epitopes and CD4 + /CD8 + cell ratio, and monitoring interferon-gamma levels at different times post-immunization. The results showed that pCCMp24, rddVTT -CCMp24 and their prime-boost immunization induced humoral and cellular immune responses. The pCCMp24/ rddVTT -CCMp24 immunization strategy increased CD8 + T cells and induced more IFN-γ-secreting cells compared with single-shot rDNA. The prime-boost immunization strategy also induced the generation of cellular immunological memory to HIV epitope peptides. These results demonstrated that prime-boost immunization with rDNA and rddVTT -CCMp24 had a tendency to induce greater cellular immune response than single-shot vaccinations, especially IFN-γ response, providing a basis for further studies. Acquired immunodeficiency syndrome (AIDS) is an epidemic disease that is difficult to both prevent and treat. Designing and developing of an effective preventive or therapeutic AIDS vaccine has been a great challenge to public health and scientific research. Recent studies in AIDS vaccine development have involved using (i) vaccine vectors, such as modified vaccinia Ankara (MVA) [1, 2] , New York vaccinia (NYVAC) [3] , fowlpox virus (FPV) [4, 5] , and Ad5 [6, 7] , (ii) various human immunodeficiency virus (HIV) immunogens, such as gp120 [8] , env [9] , tat [10] , HIV multiple epitopes [11] [12] [13] , and multi-genes [14, 15] , or (iii) different immunization routes and strategies [16, 17] . Since the first AIDS vaccine trial in 1987, more than 230 vaccine trials have been conducted [18] . Unfortunately, most of these vaccines failed to induce protection against HIV infection [19] . In a recent phase III clinical trial (RV144) in Thailand, using ALVAC-HIV (a recombinant canarypox vector that expresses gag, pol, and env) as prime and AIDSVAX B/E (a recombinant gp120 protein) as boost has shown 31.2% protective efficacy against HIV. This study has provided the first proof-of-concept for a successful HIV vaccine [20] . Recent studies have focused on developing novel DNAbased AIDS vaccines. However, to data, these vaccines have failed to confer protective efficacy in non-human primates and phase I/II human trials. To improve the immunogenicity of DNA-based vaccines, many new delivery methods and immunization strategies are being tested, including electroporation [21] , repetitive vaccine injections [22] , co-expression of cytokines, such as interleukin-12 (IL-12) [23] , 4-1BBL [24] , or granulocyte-macrophage colonystimulating factor (GM-CSF) [25] as molecular adjuvants, and prime-boost immunization strategies using heterologous vaccines which encode similar antigens [26] . CpG oligodeoxynucleotides (ODN) are powerful immunomodulatory agents capable of enhancing innate immune responses and when used as an adjuvant to improve adaptive immune responses against pathogens [27] [28] [29] . Cholera toxin (CT) has the ability to prime memory CD8 T cells, which control bacterial and viral challenges [30] . In this study, CpG ODN and CT subunit B (CTB) served as adjuvants for DNA and recombinant viral vaccines.
Vaccinia virus-based vaccines expressing HIV-associated immunogens can induce both humoral and cellular immune responses [31] . In a phase I clinical trial, the recombinant virus rMVA expressing HIV-1 virus-like particles elicited different patterns of T cell and antibody responses when used alone or in combination with DNA vaccine [17] . Several studies have also shown that immune responses can be generated in vivo in small animals or non-human primates after boost immunization with recombinant poxvirus following rDNA [26] . This prime-boost strategy using HIV rDNA for priming and recombinant vaccinia virus for boosting has been pursued by many researchers. Studies in non-human primate models using the SHIV or SIV DNA vaccine for priming and recombinant MVA for boosting have demonstrated that this regimen helped reduce viral loads in vivo and controlled disease progression [3234] . In healthy adults, regimens using a multiclade, multigene HIV-1 DNA vaccine for priming and MVA for boosting were considered safe and induced broad and potent immune responses [35, 36] . Recent research has shown that rDNA and rMVA vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of HIV-1 were weakly immunogenic but safe in HIV-1-uninfected, vaccinia virus-naive adults [37] .
In the current study, rDNA and attenuated vaccinia virus Tian Tan (VTT) vector vaccines were constructed using the antigen MEGNp24 developed previously [5, 12, 38] . Two important molecular adjuvants, CpG oligodeoxynucleotides (ODN) and cholera toxin subunit B (CTB), were combined with the vaccines to further enhance immunogenicity. Immunogenicity was evaluated in vitro and in vivo in cell models and in mice administered with individual vaccines or in combination using the prime-boost regimen. Antigenspecific humoral and cellular immune responses were analyzed for each vaccine regimen.
Materials and methods

rDNA and vaccinia virus vaccines
In the current study, rDNA pVL-CCMp24 (pCCMp24) and recombinant attenuated vaccinia virus Tian Tan (rddVTT -CCMp24 ) were prepared as described previously (Du et al., data not shown). The vaccines expressed 29 HIV dominant epitopes (24 CTL or CD8 T-cell epitopes and five B-cell epitopes), HIV-1 p24 protein, CpG ODN (5′-AAAAACGTTGACGTTAACGTTGACGTT-3′), and CTB. A schematic of the pCCMp24 and rddVTT -CCMp24 constructs is shown in Figure 1A . The vaccines were diluted to the required concentrations in phosphate-buffered saline (PBS, pH 7.4).
Immunization of mice
Six-week-old female BALB/c mice were purchased from the Laboratory Animal Center, Academy of Military Medical Sciences (Beijing, China). All animal experimental protocols were approved by the Institutional Animal Care and Use Committee of the Chinese Academy of Military Medical Science (10ZDGG007). The mice were divided into four groups of eight for immunization. Group 1 was injected intramuscularly (i.m.) with 100 μg pCCMp24, group 2 was injected i.m. with 100 μL of 1×10 6 PFU mL
1
rddVTT -CCMp24 , group 3 was primed i.m. with 100 μg pCCMp24 and boosted with 100 μL of 1×10 6 PFU mL
rddVTT -CCMp24 , and group 4 was injected i.m. with 100 μL PBS. Mice from each group were boosted three weeks after the prime vaccination using the same inoculums as for priming unless stated otherwise. The immunization schemes are shown in Figure 1B .
Preparation of splenocytes
The splenocytes of immunized mice were isolated by centrifugation with Ficoll-Hypaque lymphocyte isolation solution (TBD Science, China) according to the manufacturer's instructions. In brief, at 10 d post-booster immunization, red blood cells were treated with lysis buffer and washed twice with complete medium, and the splenocytes were suspended in complete culture medium (89% RPMI 1640; HyClone, China), 10% fetal bovine serum (HyClone), and 1% penicillin-streptomycin (HyClone). The splenocytes were then used for T cell measurements. 
Collection of serum samples
Blood samples were collected at 7, 14, 21, and 30 d following the initial vaccination (prime) and stored at 4°C for 1 h. The blood samples were centrifuged at 1000×g for 10 min, the sera were recovered and stored at 70°C until required for further testing. Sera from pre-immune mice were separated and included as the negative control.
HIV-specific antibody enzyme-linked immunosorbent assay (ELISA)
The HIV antibody detection kit (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China) was used to measure HIV-1-specific antibody titers. Briefly, 96-well ELISA plates were coated with highly purified recombinant HIV-1 antigens. One hundred microliter serum samples (test samples, as well as positive and negative control sera) were added to the appropriate wells, and the plates incubated at 37°C for 1 h in a humid environment. The plates were washed five times with 1× washing buffer and 100 μL HRP-conjugate reagent was added. Complex formation was permitted to proceed for 30 min at 37°C in a humid environment. The plates were washed five times, and 50 μL chromogen solutions A and B added to each well. Color formation was performed for approximately 30 min in the absence of light. Stop solution (50 μL/well) was added to each well to conclude the reaction. The absorbance values for each well were read at 450 nm using a microplate reader.
Interleukin-2 (IL-2) and interleukin-4 (IL-4) ELISA assay
The concentrations of IL-2 and IL-4 present in the peripheral blood of mice following booster immunization was measured using serum samples harvested at 10 d post-booster immunization using mouse IL-2 and IL-4 ELISA kits (GBD, USA) according to the manufacturer's instructions.
Lymphocyte proliferative assay
To assess the proliferative response of T lymphocytes against HIV-specific peptides, splenocytes were seeded in 96-well tissue culture plate at a cell density of 2 ) was used as the positive control. RPMI 1640 was used as the negative control. After stimulation for 24 h, the cells were washed, IFN-γ secreting cells developed using biotinylated antibody and streptavidin-HRP, and the cells counted with a Biosys Bioreader.
Statistical analysis
Statistical analysis and comparisons between immunization groups was performed using Graphpad Prism software (San Diego, CA, USA). Data are presented as the mean±standard deviation (SD). The significance of differences was calculated using the One-way ANOVA (two tailed, confidence intervals 95%), as indicated by the P-value. Differences with a P-value <0.05 were considered to be statistically significant.
Results
HIV-specific antibody response induced by different regimens
HIV-specific IgG present in the peripheral blood of mice immunized with the nominated vaccines and immunization strategies was measured at 7, 14, 21, and 30 d postimmunization by ELISA ( Figure 1B) . The results demonstrated consistent changes in IgG levels between the immunized groups and the PBS control group. As shown in Figure 1C , at 14 d post-immunization, the total antibody levels increased and then decreased. Following booster administration at 21 d, HIV-specific IgG levels again increased. At 7 d post-prime, the total antibody levels were higher for all vaccine groups analyzed when compared with the PBS control group (P<0.05), and the antibody levels produced after immunization with rddVTT -CCMp24 (Group 2) were markedly higher than for pCCMp24 (Group 1) (P<0.05; Figure 1C ). For the rDNA/virus prime-boost immunization group (Group 3), at 10 d post-boost with rddVTT -CCMp24 , the antibodies increased faster 1.2 fold than for pCCMp24-boost. The above results suggest that rddVTT -CCMp24 induced HIV-specific IgG responses, and it is obvious that the use of rddVTT -CCMp24 can enhance the immune response as a booster.
IL-2 and IL-4 secretion induced by different regimens
The concentration of cytokines IL-2 and IL-4 in the peripheral blood of mice was determined using a double antibody ELISA. As shown in Figure 2A and B, the concentrations of IL-2 and IL-4 were markedly higher for all immunization groups analyzed when compared with the PBS control 
Splenic T-lymphocyte proliferation stimulated by different regimens
The proliferation of splenic T-lymphocytes from immunized mice was determined by the WST-1 cell proliferation assay. Figure 3 shows the SI values determined for splenic Tlymphocytes stimulated by HIV epitope peptides ( Figure  3A ), or the positive control ConA ( Figure 3B ). As shown in Figure 3A , the stimulation of T-lymphocytes by HIV epitope peptides resulted in significant differences in SI values for splenocytes from the rddVTT -CCMp24 -only vaccine group (Group 2) and the rDNA/virus prime-boost group (Group 3) when compared with the PBS control group (P<0.01). No significant difference in SI values was observed between the rDNA-rDNA group (Group 1) and the PBS control group. These results indicate that both rVV-rVV and rDNA-rVV could stimulate a T-lymphocyte specific proliferative response to HIV peptides.
Flow cytometric analysis of splenocytes
The proportion of CD4 + and CD8 + T cells measured for each experimental group are presented in Figure 4 . The DNA/virus prime-boost group (Group 3) and the rdd-VTT -CCMp24 -only vaccine group (Group 2) had higher proportions of CD3 + CD4 + (P<0.05) and CD3 + CD8 + (P<0.01) T cells/10 6 splenocytes than the corresponding PBS control group. No significant difference between Group 2 and Group 3 was observed. However, the percentage of CD8 + T cells for the DNA/virus prime-boost group (Group 3) was higher than for both the pCCMp24-only vaccine group (Group 1) (P<0.01). In addition, the percentage of CD8 + T cells for the rddVTT -CCMp24 -only vaccine group was higher than for the corresponding pCCMp24-only vaccine group (P<0.05).
Increased IFN-γ secretion following prime-boost immunization and immunologic memory
To further evaluate the pCCMp24 and rddVTT -CCMp24 prime-boost immunization strategy, splenocytes from mice immunized with pCCMp24-or rddVTT -CCMp24 -only vaccine, pCCMp24-rddVTT -CCMp24 prime-boost, and PBS control were isolated and assessed. The T cell responses were (Figures 5A and 6 ). The rdd-VTT -CCMp24 -only vaccine group and pCCMp24-rdd-VTT -CCMp24 prime-boost group had considerably greater numbers of IFN-γ-positive spots (SFC)/10 5 splenocytes than was observed for the pCCMp24-only vaccine group (P<0.01). No significant differences were detected between Group 2 and Group 3 ( Figures 5A and 6 ). After stimulation with HIV epitope peptides, the rddVTT -CCMp24 -only vaccine group and pCCMp24-rddVTT -CCMp24 prime-boost group had greater numbers of SFC/10 5 splenocytes than both the pCCMp24-only and PBS control group (P<0.01; Figures 5B  and 6 ). The pCCMp24-rddVTT -CCMp24 prime-boost group had greater numbers of SFC/10 5 splenocytes than did the rddVTT -CCMp24 -only vaccine group (P<0.01; Figures 5B and splenocytes for all immunization groups was greater against inactivated rddVTT -CCMp24 than for the corresponding PBS control group (P<0.01; Figure 5C ). The pCCMp24-rddVTT -CCMp24 prime-boost group had greater numbers of SFC/10 5 splenocytes than did the pCCMp24-only group (P<0.05), rddVTT -CCMp24 -only group (not significant), and PBS group (P<0.01) against HIV epitopes ( Figures 5D and  6) . Interestingly, the pCCMp24-only group had higher average numbers of SFC/10 5 splenocytes than the rddVTT -CCMp24 -only group against HIV epitopes (P<0.01; Figure 5D ). These results indicate that rddVTT -CCMp24 boost immunization following pCCMp24 priming could induce HIV-specific cellular immune responses and immunologic memory.
Discussion
Vaccination has greatly impacted the health of human and animals in the past. To date, vaccination still plays a crucial role in preventing and controlling infectious diseases and cancers. With regard to the development of an effective AIDS vaccine, a myriad of problems and challenges have been encountered by researchers across a number studies. Such challenges include using appropriate animal models for vaccine evaluation, and effective immunogen design and immunization strategies [19, 39, 40] . VAX003 and VAX004 based on recombinant gp120 could not delay disease progression in phase III human clinical trials, and the antibodies were unable to neutralize most HIV-1 strains [8, 41] . Considering the high genetic variability of HIV, it seems unlikely that a single antigen would prove efficacious in protecting against HIV infection and disease progression. Therefore, antigen multimers, multi-epitope, or a combination of various antigens could be used to address this issue and to elicit a strong immune response against HIV [13, 15] . In previous study, 29 predominant epitopes of HIV including 23 epitopes of HIV-1, three epitopes of HIV-2, a Th cell universal epitope, a B cell universal epitope, and a tetanus toxin epitope were selected to synthesize and form a fusion gene MEGN. The p24 protein of HIV-1 was inserted into the multi-epitopes, of the aforementioned fusion gene, and named MEGNp24. To enhance the immunogenicity of the immunogen, a CpG ODN motif and CTB sequence were included upstream of MEGNp24, and the antigen designated CCMp24.
Recombinant DNA vaccines and live recombinant virusbased vaccines are the focus of many studies. Recent studies have documented the use of a number of different vaccines including viral vector vaccines or recombinant proteins as a boost following priming in an attempt to enhance the immune response induced by a single vaccine. DNA priming followed by MVA boosting, and vice versa, may provide better protection against malaria infection in mice compared with using the DNA or MVA vector alone [42] . In a previous study, different administration sequences with recombinant DNA and recombinant poxvirus were investigated in our laboratory. In the present study, virus vector booster immunization following priming with DNA was applied. Although researchers do not completely understand the principle behind the enhanced immune response for prime-boost strategies or the reason why priming with the recombinant DNA is followed by another modality such as viral vector vaccine or recombinant protein, a number of studies have documented the use of DNA/live viral recombinant in immunization regimens [43] . Several studies in non-human primates have demonstrated a significant improvement in immunogenicity for a single DNA vaccine when a viral vector vaccine was administered as a boost following priming [26] . Such synergy between DNA and viral vector vaccines was observed in non-human primates when used for boosting with poxviruses such as vaccinia virus [9, 33, 34, 44, 45] , Ad5 [46, 47] or vesicular stomatitis virus [48] .
Two attenuated vaccinia virus strains, MVA and NYVAC, have been used as vectors in vaccine research [3, 49, 50] . MVA-based therapeutic vaccines have been used in the treatment of some major chronic infections, including viral hepatitis, AIDS, and tuberculosis. Phase 1 and 2 clinical trials for MVA-based therapeutic vaccines have started to show significant results and promise for the effective treatment of chronic infectious diseases [51] . In rhesus macaques, DNA-MVA vaccine schedules expressing SIVmac-239 gag, pr, rt, and env genes, elicited high numbers of CD4 + and CD8 + T cells, and high titers and avidity for Env-specific IgG [16] . In a recent phase I clinical trial (RISVAC02), an MVA-based HIV vaccine expressing the env, gag, pol, and nef proteins of HIV-1 subtype B (MVA-B) was safe, well tolerated, and elicited strong and durable T-cell and antibody responses in 75% and 95% of volunteers [52] . The recombinant vaccinia virus vaccine rddVTT -CCMp24 used in this study was constructed previously and based on an attenuated vaccinia virus Tian Tan (deletion of TE3L and TK genes).
In the present study, the immunogenicity of various immunization strategies using pCCMp24 and rddVTT -CCMp24 expressing CTB, HIV multi-epitopes, and p24 protein (CCMp24) was investigated in mice. Booster administration of the rddVTT -CCMp24 vaccine following DNA priming generated strong humoral and T cell responses, particularly IFN-γ-mediated cellular immune responses against HIV peptides. The prime-boost immunization schedule can induced more CD8 + T cells than vaccination with DNA (pCCMp24) or virus (rddVTT -CCMp24 ) alone (Figure 4 ). In addition, rddVTT -CCMp24 booster immunization was necessary following DNA priming to enhance IFN-γ-mediated cellular immune responses upon stimulation by HIV peptide pools compared with single-shot DNA/DNA or virus/virus ( Figure 5B and D) . There was no significant difference in the levels of cytokines (IL-2 and IL-4) in peripheral blood for the three different immunization schedules (Figure 2) . With regard to HIV-specific antibody, rddVTT -CCMp24 booster immunization following DNA priming induced antibody production more rapidly than for the DNA booster, and the antibody levels showed no significant difference compared with virus/virus immunization ( Figure 1C ). These data may serve as a basis for future pre-clinical studies of recombinant DNA/vaccinia virus immunization schedules.
